Intraday Market Movement and Volatility
On 26 Nov 2025, Parmax Pharma recorded an intraday low of Rs.28, representing a notable drop of 10.26% from previous levels. The stock exhibited high volatility throughout the trading session, with an intraday volatility of 5.41% calculated from the weighted average price. This movement contrasted with the broader market trend, where the Sensex advanced by 0.89%, closing at 85,337.29 points after a flat opening. The Sensex is currently trading close to its 52-week high of 85,801.70, supported by bullish moving averages and a three-week consecutive rise.
Parmax Pharma’s performance today lagged behind the Pharmaceuticals & Biotechnology sector by 10.9%, underscoring the stock’s relative weakness within its industry group. Additionally, the share price remains below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained downward pressure.
Our latest monthly pick, this Large Cap from Aluminium & Aluminium Products, is outperforming the market! See the analysis that helped our Investment Committee select this winner.
- - Market-beating performance
- - Committee-backed winner
- - Aluminium & Aluminium Products standout
Long-Term Price and Performance Context
Over the past year, Parmax Pharma’s stock has declined by 38.66%, a stark contrast to the Sensex’s gain of 6.67% during the same period. The stock’s 52-week high was Rs.55.02, indicating that the current price level represents a near 49% reduction from its peak. This extended downtrend reflects persistent headwinds faced by the company.
Financial Metrics and Business Performance
Parmax Pharma’s financial data reveals several areas of concern. The company’s net sales for the nine months ended September 2025 stood at Rs.9.30 crores, showing a contraction of 56.46% compared to the previous period. Quarterly profit before tax excluding other income registered a loss of Rs.2.09 crores, while the net profit after tax for the quarter was a loss of Rs.2.08 crores. These figures highlight a challenging revenue environment and pressure on profitability.
The company’s long-term growth metrics also indicate subdued expansion. Net sales have declined at an annual rate of 4.56% over the last five years, while operating profit has shown a modest rate of 6.65%. The ability to service debt remains constrained, with an average EBIT to interest ratio of 0.66, suggesting limited coverage of interest obligations from operating earnings.
Valuation and Risk Considerations
Parmax Pharma’s valuation appears stretched relative to its historical averages, with the stock trading at levels that imply elevated risk. The company’s book value is negative, pointing to weak long-term fundamental strength. Profitability has also declined by 7% over the past year, compounding concerns about the company’s financial health.
In addition to the financial challenges, the stock has underperformed the BSE500 index over multiple time frames, including the last three years, one year, and three months. This underperformance reflects both sector-specific and company-specific factors weighing on investor sentiment.
Shareholding Pattern
The majority of Parmax Pharma’s shares are held by non-institutional investors, which may influence liquidity and trading dynamics. Institutional participation remains limited, potentially affecting the stock’s market behaviour during periods of volatility.
Parmax Pharma or something better? Our SwitchER feature analyzes this micro-cap Pharmaceuticals & Biotechnology stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Market Environment and Sector Overview
While Parmax Pharma’s shares have declined, the broader market environment has shown resilience. The Sensex’s recent gains have been supported by mid-cap stocks, with the BSE Mid Cap index rising by 1.01% today. The Pharmaceuticals & Biotechnology sector, however, has experienced mixed performance, with Parmax Pharma’s relative weakness contributing to sector volatility.
Overall, the stock’s current price level at Rs.28 represents a significant milestone, reflecting the cumulative impact of subdued sales growth, profitability pressures, and valuation concerns. The trading below all major moving averages further emphasises the prevailing downward momentum.
Summary
Parmax Pharma’s stock reaching a 52-week low of Rs.28 highlights ongoing challenges within the company’s financial and operational framework. The stock’s underperformance relative to the sector and broader market indices, combined with weak sales and profit figures, underscores the difficulties faced by the company. Despite a positive market backdrop, the stock remains under pressure, with valuation and fundamental metrics signalling caution.
Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →
